Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the manifestations of non-classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency across different life stages, but reports no new findings.

This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.

Hormonal imbalances in congenital adrenal hyperplasia cause acne.

This study reviewed the current understanding of congenital adrenal hyperplasia from 21-hydroxylase deficiency, highlighting the impact of universal newborn screening in reducing mortality and discussing ongoing treatment challenges and future therapeutic prospects.

This study found that ethanol extract of Syzygium aromaticum (clove) leaves significantly improved lipid profiles and increased body weight in testosterone-induced benign prostatic hyperplasia rats, suggesting potential anti-hyperlipidemic effects and modulation of body weight through metabolic activity.

In this study, long-term low-dose finasteride use in men with alopecia was associated with a significant reduction in the diagnosis of benign prostatic hyperplasia and prostate cancer, although further research is needed to understand the mechanisms and long-term effects.

The authors concluded that while finasteride 1 mg affects prostate-related pathways, evidence is insufficient to prove clinical benefits for prostate outcomes compared to the established effectiveness of finasteride 5 mg.

In this study, high-dose Arachis hypogaea root extract significantly reduced prostate weight and markers of glandular hyperplasia in testosterone-induced BPH in mice, with associated changes in inflammatory gene expression and beneficial shifts in gut microbiota.

In this case study, a woman with congenital adrenal hyperplasia experienced substantial improvement in musculoskeletal and neurobehavioral symptoms after low-dose testosterone therapy, highlighting its potential role in managing chronic glucocorticoid overtreatment effects.

This study found that 44.3% of patients with benign prostatic hyperplasia experienced high anxiety levels, which were significantly associated with residual symptoms and demographic factors.

This case report presents a rare instance of recurrent ACTH-independent Cushing’s syndrome due to PBMAH, coinciding with the development of a pheochromocytoma, highlighting the need for thorough reevaluation in similar recurring cases.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

In this study, a pH-responsive microneedle patch was developed, showing potential in rat models for treating spinal cord injuries by reducing inflammation, promoting nerve regeneration, and supporting neurogenesis, which contributed to improved motor and neurological recovery.

In this case report, a 46-year-old woman initially diagnosed with 21-hydroxylase deficiency congenital adrenal hyperplasia was later identified as having 3β-HSD2 deficiency after further investigation, highlighting the need for awareness of rarer CAH forms to prevent delayed diagnosis and insufficient treatment.

Single-needle radiofrequency is effective and safe for treating facial sebaceous hyperplasia.

This study found that among children with 21-hydroxylase deficiency, there is a strong correlation between severe genetic variants and clinical outcomes, but the correlation weakens with milder variants, indicating the limitations of relying solely on NGS for diagnosis.

In this study, researchers observed that Cuscuta reflexa extract mitigated inflammation and oxidative stress in testosterone-induced benign prostatic hypertrophy in Wistar rats, suggesting its potential as an adjunctive therapy for BPH.

This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.

This review reported that while finasteride is effective for treating androgenetic alopecia and benign prostatic hyperplasia, it may cause adverse effects such as sexual dysfunction and psychological symptoms, which require careful patient education and management to ensure treatment adherence and satisfaction.

This case report describes a 37-year-old female with non-classical congenital adrenal hyperplasia who presented with severe acne, progressive hair loss, and primary infertility, managed with prednisolone.

In this study, researchers found that fenugreek seed extract reduced prostate size, DHT levels, and cell proliferation in a testosterone-induced BPH rat model while modulating various genetic expressions, suggesting its potential as an alternative treatment for benign prostatic hyperplasia.

Plant-based treatments may help reduce BPH symptoms, but more research is needed.

In this retrospective cohort study, researchers found no significant difference between finasteride and dutasteride in terms of reducing prostate volume or adverse effects among patients with benign prostatic hyperplasia, although both drugs improved lower urinary tract symptoms over one year by reducing prostate volume.

This article critiques a study on finasteride use among individuals with benign prostatic hyperplasia and androgenetic alopecia, highlighting the flawed methodology and potential confounding effects of hair loss on mental health, which confuses interpretation of psychiatric risk.

This case report details a postmenopausal woman whose hyperandrogenism was attributed to ovarian stromal hyperplasia, ultimately resolved with bilateral salpingo-oophorectomy.

This case report describes a patient with an ovarian steroid cell tumor that initially presented as non-classical adrenal hyperplasia, emphasizing the difficulty in differential diagnosis with hyperandrogenism and the importance of close clinical monitoring.

This case report highlights the challenge of differentiating between non-classical adrenal hyperplasia and steroid cell tumors of the ovary in a patient presenting with hyperandrogenism.

This study found that among patients over 45 with lower urinary tract symptoms due to benign prostatic hyperplasia, those with androgenic alopecia had worse symptoms and higher testosterone levels than those without baldness.

This study found that finasteride users had a very low rate of psychiatric side effects, with no significant increase in BPH patients and a slight increase in anxiety and depression among AGA patients.

In this report, a 22-year-old woman with congenital adrenal hyperplasia due to 21-hydroxylase deficiency underwent treatment with hydrocortisone and spironolactone, followed by feminization surgery, which subsequently led to the development of secondary sexual characteristics and regular menstruation.